Peritoneal-plasma barrier
- 1 January 1996
- book chapter
- Published by Springer Nature
- Vol. 82, 53-63
- https://doi.org/10.1007/978-1-4613-1247-5_4
Abstract
Intraperitoneal chemotherapy has been described as a therapeutic option in the management of a variety of malignancies that occur primarily in a locoregional manner [1]. Potential benefits of this technique may occur in tumors principally confined to the peritoneal cavity (gastrointestinal malignancies and ovarian carcinoma) [2,3]. Theoretically, the use of intraperitoneal drug could eliminate local tumor spread as a mechanism of cancer recurrence both in the abdomen and in the pelvis.Keywords
This publication has 13 references indexed in Scilit:
- Physiology of the Peritoneum: Implications for Peritoneal DialysisMedical Clinics of North America, 1990
- Drug Therapy in Patients Undergoing Continuous Ambulatory Peritoneal DialysisClinical Pharmacokinetics, 1990
- Peritoneal carcinomatosis: Anatomy, physiology, diagnosis, managementCurrent Problems in Cancer, 1986
- Prolonged Treatment Schedules with Intraperitoneal 5-Fluorouracil Diminish the Local-Regional Nature of Drug DistributionAmerican Journal of Clinical Oncology, 1986
- Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysisClinical Pharmacology & Therapeutics, 1983
- Permeability of the diaphragmatic mesothelium: The ultrastructural basis for “stomata”Journal of Anatomy, 1978
- Transport of Model Compounds across the Peritoneal Membrane in the RatPharmacology, 1978
- Studies on transport of macromolecules and small particles across mesothelial cells of the mouse omentum: I. Morphologic aspectsExperimental Cell Research, 1971
- Surgical treatment of ulcerative colisisGastroenterologia Japonica, 1970
- Peritoneal dialysis efficiency in relation to body weightJournal of Pediatric Surgery, 1966